This article is more than 5 years old. Information may no longer be current.

Allergan's TrueTear granted marketing authorization

Issue: May 25, 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The TrueTear intranasal tear neurostimulator has been granted marketing authorization from the FDA, according to an Allergan press release.

The hand-held stimulator is the first FDA-cleared device for temporarily increasing tear production during neurostimulation. The device has disposable tips and is inserted into the nasal cavity to induce the production of tears, the release said.

“TrueTear represents a technological breakthrough for eye care professionals as it delivers an effective, non-invasive and drug-free way to temporarily increase tear production,” David Nicholson, chief R&D officer at Allergan, said in the release.